Dicerna Pharmaceuticals Stock Fundamentals
Dicerna Pharmaceuticals fundamentals help investors to digest information that contributes to Dicerna Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dicerna Stock. The fundamental analysis module provides a way to measure Dicerna Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dicerna Pharmaceuticals stock.
Dicerna |
Dicerna Pharmaceuticals Company Operating Margin Analysis
Dicerna Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Dicerna Pharmaceuticals Operating Margin | (62.88) % |
Most of Dicerna Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dicerna Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Dicerna Pharmaceuticals has an Operating Margin of -62.88%. This is 79.25% higher than that of the Healthcare sector and 43.89% lower than that of the Biotechnology industry. The operating margin for all United States stocks is notably higher than that of the company.
Dicerna Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Dicerna Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Dicerna Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dicerna Pharmaceuticals competition to find correlations between indicators driving Dicerna Pharmaceuticals's intrinsic value. More Info.Dicerna Pharmaceuticals is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Dicerna Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Dicerna Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dicerna Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Dicerna Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dicerna Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dicerna Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dicerna Pharmaceuticals by comparing valuation metrics of similar companies.Dicerna Pharmaceuticals is currently under evaluation in operating margin category among related companies.
Dicerna Fundamentals
| Return On Equity | -95.22 | |||
| Return On Asset | -10.43 | |||
| Profit Margin | (64.53) % | |||
| Operating Margin | (62.88) % | |||
| Current Valuation | 2.48 B | |||
| Shares Outstanding | 77.91 M | |||
| Shares Owned By Insiders | 7.43 % | |||
| Shares Owned By Institutions | 88.54 % | |||
| Number Of Shares Shorted | 4.77 M | |||
| Price To Earning | (1.58) X | |||
| Price To Book | 27.64 X | |||
| Price To Sales | 15.44 X | |||
| Revenue | 192.85 M | |||
| Gross Profit | (41.08 M) | |||
| EBITDA | (116.73 M) | |||
| Net Income | (124.44 M) | |||
| Cash And Equivalents | 565.51 M | |||
| Cash Per Share | 7.26 X | |||
| Total Debt | 64.42 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 2.46 X | |||
| Book Value Per Share | 1.38 X | |||
| Cash Flow From Operations | 21.05 M | |||
| Short Ratio | 0.84 X | |||
| Earnings Per Share | (1.63) X | |||
| Number Of Employees | 302 | |||
| Beta | 0.79 | |||
| Market Capitalization | 2.98 B | |||
| Total Asset | 62.95 M | |||
| Retained Earnings | (539.14 M) | |||
| Working Capital | 49.56 M | |||
| Current Asset | 59.38 M | |||
| Current Liabilities | 9.82 M | |||
| Z Score | 16.1 |
Pair Trading with Dicerna Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dicerna Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dicerna Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Dicerna Stock
If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |